Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).
1 finding from 1 review
Adverse events: minor (hirsutism) · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin may leads to higher adverse events: minor (hirsutism) compared with oral azathioprine (low certainty).
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
It is very uncertain whether budesonide 6‐9 mg changes continued remission at 12 months compared with azathioprine 2‐2.5 mg/kg (very low certainty).
1 finding from 1 review
Adverse events (Ardizzone 2003) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Oren 1997) compared with 6‐MP or azathioprine (very low certainty).
3 findings from 1 review
RR 1.23 [0.08, 18.74]
1 study · 58 participants
Very low
RR 2.13 [0.22, 21.17]
1 study · 31 participants
Very low
RR 1 [0.22, 4.52]
1 study · 54 participants
Very low
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
Methotrexate showed no clear difference in failure to enter remission or possible remission at 24‐36 weeks… compared with 6‐MP or azathioprine (low certainty).
3 findings from 1 review
RR 1.36 [0.97, 1.92]
1 study · 58 participants
Low
RR 3.2 [0.37, 27.49]
1 study · 31 participants
Very low
RR 1.2 [0.63, 2.29]
1 study · 54 participants
Very low
Intervention not reported
Acute pancreatitis · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes acute pancreatitis (very low certainty).
1 finding from 1 review
Intervention not reported
Bone marrow suppression · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes bone marrow suppression (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
1 finding from 1 review
Intervention not reported
Any adverse event · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes any adverse event (very low certainty).
1 finding from 1 review
Intervention not reported
Withdrawal due to adverse event · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes withdrawal due to adverse event (very low certainty).
1 finding from 1 review
Maintenance of remission · maintenance of remission in Crohn's disease
It is very uncertain whether 6‐Mercaptopurine changes maintenance of remission compared with methotrexate (very low certainty).
1 finding from 1 review
Adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether 6‐Mercaptopurine changes adverse events compared with methotrexate (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether 6‐Mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
1 finding from 1 review
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).
1 finding from 1 review